Research programme: schizophrenia therapeutics - Boehringer Ingelheim/Saniona
Latest Information Update: 28 Apr 2024
At a glance
- Originator Saniona
- Developer Boehringer Ingelheim; Saniona
- Class Antipsychotics; Small molecules
- Mechanism of Action Ion channel modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Schizophrenia
Most Recent Events
- 28 Apr 2024 No recent reports of development identified for preclinical development in Schizophrenia in Denmark
- 28 Apr 2024 No recent reports of development identified for preclinical development in Schizophrenia in Germany
- 05 Nov 2020 Saniona regains global rights for GABAa5 negative allosteric modulator programme from Boehringer Ingelheim